Edwards Syndrome (Trisomy 18) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Edwards Syndrome (Trisomy 18) Market Outlook

Thelansis’s “Edwards Syndrome (Trisomy 18) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Edwards Syndrome (Trisomy 18) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Edwards Syndrome (Trisomy 18) Overview

Edwards syndrome (Trisomy 18) is an autosomal chromosomal disorder characterized by an additional copy of chromosome 18. This condition is classified as one of the autosomal trisomy syndromes, with trisomy 21 being the most common. The occurrence of Edwards syndrome is primarily attributed to the presence of an extra copy of chromosome 18q. There are three distinct types of Edwards syndrome: complete trisomy 18, which accounts for approximately 94% of cases, mosaic trisomy 18, which constitutes less than 5%; and partial trisomy 18, which is responsible for 2% of cases. The risk of recurrence for complete trisomy 18 in subsequent pregnancies is estimated to be between 0.5% and 1%. The characteristic features of Edwards syndrome are believed to be associated with three copies of specific regions on the long arm of chromosome 18, specifically 18q12.1 to 18q21.2 and 18q22.3 to 18qter. Severe intellectual disability observed in individuals with Edwards syndrome may be linked to the trisomy of the 18q12.1 to 18q21.2 region. Notably, trisomy of the short arm of chromosome 18 (18p) does not seem to contribute significantly to the significant features of Edwards syndrome. Currently, there is no definitive treatment available for Edwards syndrome. Approximately 40% of affected fetuses do not survive labor, and about one-third of the surviving fetuses are born prematurely. The median survival time for individuals with Edwards syndrome ranges from 3 days to 14.5 days. The survival rates are approximately 60% to 75% at the end of the first week, 20% to 40% at the end of the first month, and 10% at the end of the first year. Only 5% to 10% of individuals with Edwards syndrome survive beyond their first year.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Edwards Syndrome (Trisomy 18) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034